All In Biotech

Drug Trial Radar · NCT05766267

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Nov 21, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Sponsor type
Federal agency
Collaborators
Tuberculosis Trials Consortium
First posted
Mar 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week. The first 17-week regimen is 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus rifabutin (Rb) (BMZRB) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb) (2 BMZRb/2 BMRb, Arm 1) The Second 17-week regimen is 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus delamanid (D or DLM); (BMZD) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM) (2 BMZD/2 BMD, Arm 2) The standard 26-week treatment control regimen which is two months of isoniazid, rifampin, ethambutol, and pyrazinamide (2HRZE) followed by four months of isoniazid and rifampin (4HR); (2HRZE/4HR, Arm 3) Target enrollment is 288 male and female participants (96/arm). participants. Participants will be followed until 78 weeks post-randomization, or until the last enrolled participant completes 52 weeks post-randomization, whichever comes first.

Conditions

  • Tuberculosis, Pulmonary
  • Tuberculosis Infection

Interventions

  • RifabutinDrug

    Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)

  • DelamanidDrug

    Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)

  • BedaquilineDrug

    Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).

  • MoxifloxacinDrug

    Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).

  • PyrazinamideDrug

    Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).

  • IsoniazidDrug

    Isoniazid is part of control regimen (HRZE).

  • RifampinDrug

    Rifampin is part of control regimen (HRZE).

  • EthambutolDrug

    Ethambutol is part of control regimen (HRZE).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to sputum culture negative in liquid media after study treatment among participants in Experimental Regimens (2 BZMRb/ 2 BMRb, Arm 1) and (2 BMZD/ 2 BMD, Arm 2) compared to Control (2HRZE/4HR, Arm 3) in modified intention-to-treat group (ITT)Time frame: 17 weeks

Locations

8 sites in 6 countries. Site status is shown where the registry gives one.

  • TBTC Site 26 Seattle & King County TB Control Program

    Seattle, Washington

  • McGill University Health Centre

    Montreal, Canada

  • Vancouver, British Columbia Centre for Disease Control

    Vancouver, Canada

  • TBTC Site 67 GHESKIO centers IMIS

    Port-au-Prince, Ouest, Haiti

  • TBTC Site 45 Les Centres Gheskio (INLR)

    Port-au-Prince, Ouest, Haiti

  • TBTC Site 09 University of Cape Town Lung Institute (Pty) Ltd

    Mowbray, Cape Town, South Africa

  • TBTC Site 30 Uganda-Case Western Reserve Research Collaboration

    Kampala, Uganda

  • TBTC Site 76 CAB-V. Can Tho Province, Vietnam - Thot Not District TB Unit

    Can Tho, Can Tho City, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.